Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 396

Results For "IP"

11174 News Found

Dr. Jitendra Singh inaugurates 'National Biobank' at CSIR-IGIB
Policy | July 07, 2025

Dr. Jitendra Singh inaugurates 'National Biobank' at CSIR-IGIB

CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders


Biocon Biologics receives MHRA UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars
News | July 07, 2025

Biocon Biologics receives MHRA UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars

Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone


Sigachi Industries appoints Lijo Stephen Chacko as Deputy Group CEO
People | July 07, 2025

Sigachi Industries appoints Lijo Stephen Chacko as Deputy Group CEO

Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries


SPARC incorporates subsidiary ‘Genokine Biotech’
News | July 07, 2025

SPARC incorporates subsidiary ‘Genokine Biotech’

The wholly owned subsidiary will carry on the business of all types of research and development and other related services


GACL flags of first dispatch of Benzyl Alcohol and Benzaldehyde
News | July 06, 2025

GACL flags of first dispatch of Benzyl Alcohol and Benzaldehyde

The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde


Shilpa Pharma Lifesciences Unit-1 inspected by ANVISA
Drug Approval | July 06, 2025

Shilpa Pharma Lifesciences Unit-1 inspected by ANVISA

The audit has been concluded with no major observations


Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer
Clinical Trials | July 06, 2025

Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone


Lupin launches nasal spray in US
News | July 04, 2025

Lupin launches nasal spray in US

Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals


Faron publishes study highlighting role of sClever-1 as immune blocker in cancer
News | July 04, 2025

Faron publishes study highlighting role of sClever-1 as immune blocker in cancer

The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells